- Research Grants
Opher Gileadi obtained his B.Sc. in Biology (1983) and PhD in Biochemistry at the Hebrew University (1989) and was then a postdoctoral fellow at Stanford University Medical School. Subsequently he led a research group at the Weizmann Institute of Science. Since 2004 he has been at the Structural Genomics Consortium (SGC) at the University of Oxford, first as head of the Bioytechnology group, then as Principal Investigator of the Genome Integrity & Repair Group. Opher studied the biochemical basis of gene expression and DNA repair using a variety of approaches, including the analysis of differential mRNA in human trophoblast cells, transcription factors studies using purified systems and genetics of yeast, and only analyzes molecule of protein: DNA interactions. The SGC (Structural Genomics Consortium), Opher established the group of biotechnology, developing high-yield production methods (high-throughput) of human proteins for crystallization. He now leads the Genome Integrity Group, which studies proteins and DNA repair proteins associated with human genetic disease. Recent work includes helicases structures RecQ DNA endonucleases and DNA repair cross-link and biochemical characterization of mutant genes congenital syndrome Carpenter and Dyserythropoietic congenital anemia. It is currently also developing methods to intervene in DNA repair using small molecules, such as new inhibitors of the Bloom DNA helicase. In July 2015, Opher has relocated to Brazil to head the SGC Kinase Chemical Biology Center at the State University of Campinas (UNICAMP). (Source: Lattes Curriculum)
Many of the discoveries from the rapidly expanding genomic sciences are not effectively utilized in medicine, agriculture and industry. This is partly because of the disconnection between scientists in different disciplines, and because much of the translational research done in both industry and academia is patent-protected and not published in a timely manner. This INCT proposal addre...
One of the ways to get new medicines is to find the right targets, which are better predicted when the human biology is understood. To study human biology, tools such as genetic approaches and chemical inhibition are used to reveal the functions of a protein and together they can validate (or invalidate) a hypothetical therapeutic target. One of the protein classes that has been demonst...
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
|Data from Web of Science|